Gene and cell therapies have made important medical advances over the past three decade, developing technologies and testing novel therapies in
multiple human clinical trials of many diseases.
Not exact matches
By printing
multiple lung airways — or any other afflicted organ — from a
human patient and testing drugs on them, pharma companies can bypass the ethically challenged practice of testing on animals and proceed to
human clinical trials with greater confidence the drugs will actually work, according to Wadsworth.
«The study results elucidate the molecular mechanisms underlying disease progression in
multiple sclerosis models, providing a basis for future
clinical trials to determine safety and efficacy of these chemical agents in
humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.
For example, Matt Krause, director of
human resources at CV Therapeutics, says, «Our research programs include
multiple, cutting - edge cardiovascular product candidates in various stages of
clinical trials and preclinical programs, all of which rely heavily on the contributions from our many B.S. - and M.S. - level scientists.»
Inosine has also been administered in
human clinical trials for
multiple sclerosis and Parkinson's disease and has been proven to be safe in doses up 3000 mg / day.
Therapies applying this paradigm to clear β - amyloid protein (Aβ) plaques and soluble aggregates from patients with Alzheimer's disease (AD) is an extremely active field of research, with
multiple active and passive Aβ vaccines currently in
human clinical trials.
With
multiple therapeutic approaches now either in early
clinical trials or nearing
human testing, optimism is starting to mount that one of these approaches will ultimately prove a success.
Dr. Falk is also PI of an NIH, pharma, and philanthropic funded translational research laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and
human tissue models of genetic - based respiratory chain dysfunction, and directs
multiple clinical treatment
trials in mitochondrial disease patients.
Whereas enthusiasm for fasting is increasing,
clinical relevance remains low because of insufficient
human data, including almost nonexistent controlled
trials (21, 33 — 36), few
clinical outcomes studies (37, 38), lack of correction for inflated type I error rates from
multiple hypothesis tests, and limited safety data (39 — 41).